Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study-Reference-Cited by-同舟云学术

Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study

Published:2022-10 Issue:4 Volume:87 Page:841-843
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Khanna Urmi,Gallop Joshua,Ellis Ariana,Hu Jeffery,Galadari Abdulaziz,Saklecha Anokhi,Gordon Steve M.,Husni M. Elaine,Rieder Florian,Fernandez Anthony P.

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. Utility of repeat latent tuberculosis testing with the QuantiFERON-TB Gold test in patients with psoriasis treated with tumour necrosis factor-α inhibitors at a single U.S. institution;Ya;Br J Dermatol,2020

2. Conversion of tuberculosis screening tests during biologic therapy among veteran patient population with rheumatic disease;Pattanaik;ACR Open Rheumatol,2019

3. Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications;Ellis;J Am Acad Dermatol,2020

4. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis;Elewski;JAMA Dermatol,2021

5. Waste in the US health care system: estimated costs and potential for savings;Shrank;JAMA,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Annual tuberculosis screening in patients on biologics has questionable value;Journal of the American Academy of Dermatology;2024-03

2. Dermatology practice updates in mycobacterial disease;International Journal of Dermatology;2023-12-14

3. Safety of Biologics for Psoriatic Patients with Latent Tuberculosis;Clinical, Cosmetic and Investigational Dermatology;2023-08

4. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients;Expert Opinion on Drug Safety;2023-01-02

5. Reply to “Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study”;Journal of the American Academy of Dermatology;2022-12